Senior Management

Patrick Fourteau
Chief Executive Officer & President

Patrick Fourteau served as President and Chief Executive Officer of Shionogi US operations, from 2008 until 2010 following the acquisition of Sciele by Shionogi & Co., LTD. in 2008, Mr. Fourteau served as President, CEO, member of the board of directors of Sciele Pharma, Inc. from 2003 until 2008. Mr. Fourteau served as President of the US sales operations of inVentiv Health, Inc. from 2000 to 2002, President of various divisions of St. Jude Medical, Inc. from 1995 to 2000 and as an Executive of Eli Lilly and Company. He serves on the Board of Insys Therapeutics, Inc. Mr. Fourteau earned his B.A. and M.A. in Mathematics from the University of California, Berkeley and an MBA from Harvard University.

Harry H. Penner, Jr.
Executive Chairman, Founder

Mr. Penner has been a founder of seven other biotechnology companies, among which are Rib-X Pharmaceuticals (now Melinta Therapeutics), Prevention Pharmaceuticals, Affinimark Technologies, and Marinus Pharmaceuticals. From 1993 to 2001, he was President and Chief Executive Officer of Neurogen Corporation. Previously, he served as Executive Vice President of Novo Nordisk A/S and President of Novo Nordisk of North America, Inc. from 1988 to 1993. From 1985 to 1988, he was Executive Vice President and General Counsel of Novo Nordisk A/S. Mr. Penner, who also serves on the board of Celldex Therapeutics (CLDX), earned a B.A. from the University of Virginia, a J.D. from Fordham University, and an L.L.M. from New York University.

Larry Dillaha, M.D.
Executive Vice President Operations

Prior to joining our company, Larry Dillaha, M.D. has served as the Chief Medical Officer at Insys Therapeutics, Inc. from April 2010 until May 2014. From 2006 until 2010, Dr. Dillaha served as EVP and Chief Medical Officer for Shionogi and Co., Ltd. (formerly Sciele Pharma, Inc.). While at Sciele, Dr. Dillaha oversaw the development and successful NDA approvals of 2 cardiology products, SULAR low dose, a LifeCycle extension of SULAR, and TRIGLIDE a fenofibrate. He has extensive experience in planning and overseeing clinical development programs. Dr. Dillaha served as Medical Director for Sanofi-Aventis. Dr. Dillaha earned his M.D. degree as well as a B.A. in Biology from the University of Tennessee.

Jeff Patrick, Pharm.D.
Chief Scientific Officer

Dr. Patrick has over fifteen years of scientific and medical experience in the pharmaceutical industry. Dr. Patrick has held a variety of leadership roles at Myogen, Gilead Sciences, Dyax and Mallinckrodt.

At Mallinckrodt, Jeff served as the Global Vice President, Medical Affairs, where he helped Mallinckrodt transition into a fully integrated specialty pharmaceutical company including assimilating a series of business acquisitions, including CNS Therapeutics, Cadence and Questcor.

Jeff holds a Doctorate of Pharmacy from the University of Tennessee Health Science Center, and completed a Specialty Residency in Ambulatory Care at the University of Tennessee Medical Center, Knoxville.

Michael Milligan
Chief Financial Officer

Prior to joining New Haven Pharmaceuticals, Michael Milligan served as the Chief Accounting Officer at Shionogi, Inc. from October 2008 until November 2014 where he was responsible for accounting, financial reporting, internal controls, tax, payroll and risk management. Prior to Shionogi, Mr. Milligan served in multiple accounting and finance positions at Sciele, Inc. culminating as Vice-President Finance. Prior to Sciele, Mr. Milligan worked for Ernst & Young and KPMG in their assurance practices concentrating on manufacturing, retail and distribution SEC clients. Mr. Milligan earned his M.B.A. from Georgia State University as well as a B.B.A. in Accounting from the University of Miami.

Kimberly Wehger
Chief Information Officer

Kimberly has nearly 20 years of experience in the pharmaceutical industry, with 7 years of service as a member of information technology senior management. She has served in a variety of technology disciplines, including development, applications, and relationship management. Most recently, Kimberly was Director of Business Engagement at Alexion Pharmaceuticals. As a direct report to the CIO, she led the global Business Analysis, Application Administration, and Development teams. While there, she led several large-scale, multi-million dollar initiatives, including CRM and document management system implementations. Prior to Alexion, Kimberly held technology positions at Purdue Pharma in sales systems, web technology, and development.

Kimberly earned her Bachelor of Arts from the Binghamton University and her Master of Arts from Southern Connecticut State University.